values management board of directors corporate governance governance documents risk management careers about us clinical studies clinical studies products products meltdose technology technology investor relations releases download center calendar financial information outlook stock information historic stock lookup investment calculator order depth and latest trades dividend history analyst coverage general meetings investor media media formulating for the future of transplant patient therapy veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients . our unique patented delivery technology meltdose is designed to enhance the absorption and bioavailability of select orally administered drugs . veloxis is an international company with headquarters in h rsholm denmark and a fully owned subsidiary in edison new jersey usa . veloxis is committed to patient access and financial support for kidney transplant patients . learn more about our prescription cost savings programs click here featured events nov 17 2016 q3 results investor call webcast conference call at 3 00 pm cet please dial in 5 10 minutes prior to the start time using the number conference id below . uk 44 0 20 3427 1903 us 1212 444 0895 dk 4532 71 16 59 confirmation code 3090135 stock information quick links releases products outlook corporate governance our management team analyst coverage rights issue 2012 shareholder briefcase email alerts download library snapshot mobile investor rss news feeds print page email page share this on delicious digg facebook linkedin twitter what is this veloxis pharmaceuticals a s c o plesner advokatfirma amerika plads 37 2100 k benhavn tel. 4570333300 cvr no. 26 52 77 67 info veloxis.com